OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr Gadi on Results From of the DESTINY-Breast06 Trial in HR+/HER2-Low Breast Cancer

June 7th 2024

VK Gadi, MD, PhD, discusses primary results from the phase 3 DESTINY-Breast06 trial of trastuzumab deruxtecan in HR-positive, HER2-low breast cancer.

Dr Jhaveri on the Implications of Treatment With RLY-2608 in Advanced ER+ Breast Cancer

June 7th 2024

Komal Jhaveri, MD, FACP, discusses the implications of investigating treatment with RLY-2608 in patients with PIK3CA-mutant advanced ER+ breast cancer.

Dr Pegram on the Implications and Safety of T-DXd in HR+/HER2-Low and -Ultralow Breast Cancer

June 7th 2024

Mark Pegram, MD, discusses implications of and safety data from the primary analysis of the DESTINY-Breast06 trial in HR+/HER2– metastatic breast cancer.

Dr Spigel on the Efficacy of Durvalumab Consolidation Therapy in LS-SCLC

June 7th 2024

David R. Spigel, MD, discusses findings from the phase 3 ADRIATIC trial in patients with limited-stage small cell lung cancer.

Dr Adam on the Efficacy of Liver Transplantation With Chemo in Unresectable CRC Liver Metastases

June 7th 2024

Rene Adam, MD, PhD, discusses the use of chemotherapy and liver transplant in patients with definitively unresectable colorectal liver metastases.

Dr Hughes on Efficacy Data for Asciminib in Newly Diagnosed Ph+ CP-CML

June 7th 2024

Timothy Hughes, MD, MBBS, FRACP, FRCPA discussed findings from the ASC4FIRST trial comparing asciminib vs investigator-selected TKIs in CP-CML.

Dr Sekeres on the FDA Approval of Imetelstat in Lower-Risk MDS With Anemia

June 7th 2024

Mikkael A. Sekeres, MD, discusses the significance of the FDA approval of imetelstat for patients with lower-risk MDS and transfusion-dependent anemia.

Dr Carraway on Currently Available Treatment Options for AML

June 6th 2024

Hetty E. Carraway, MD, MBA, discusses current treatment strategies available for patients with acute myeloid leukemia.

Dr Phillips on the Safety and Efficacy of Glofitamab in Relapsed/Refractory MCL

June 6th 2024

Tycel Phillips, MD, MPH, discusses updated efficacy and safety data with glofitamab for the treatment of relapsed/refractory mantle cell lymphoma.

Dr Shadman on the Comparative Efficacy of Currently Available BTK Inhibitors in CLL

June 6th 2024

Mazyar Shadman, MD, MPH, discusses results from a network meta-analysis on the comparative efficacy of BTK inhibitors in relapsed/refractory CLL.

Dr D’Amico on Genomic Classifiers in Prostate Cancer

June 5th 2024

Anthony V. D'Amico, MD, PhD, discusses the Decipher Genomic Classifier in prostate cancer treatment.

Dr Kishtagari on JAK Inhibitor Selection for Myelofibrosis in the Community Setting

June 5th 2024

Ashwin Kishtagari, MD, discusses the selection process of JAK inhibitors for patients with myelofibrosis being treated in a community setting.

Dr Bochner on Genetic Heterogeneity in Bladder Cancer

June 5th 2024

Bernard H. Bochner, MD, FACS discusses genomic complexity and heterogeneity in bladder cancer tumors.

Dr Garrido-Castro on Sacituzumab Govitecan With or Without Pembrolizumab in Metastatic HR+/HER2– Breast Cancer

June 5th 2024

Ana Christina Garrido-Castro, MD, on sacituzumab govitecan with/without pembrolizumab in metastatic hormone receptor–positive, HER2-negative breast cancer.

Dr Cremolini on the Utility of xM and xM NeXT Personal Dx MRD Assays

June 4th 2024

Chiara Cremolini, MD, PhD, discusses the use of the xM and NeXT Personal Dx assays in the detection of minimal residual disease in patients with cancer.

Dr Landgren on the Rationale for Utilizing MRD as a Clinical Trial End Point in Myeloma

June 4th 2024

Ola Landgren, MD, PhD, discusses the background for utilizing MRD as a clinical trial end point when evaluating multiple myeloma treatment.

Dr Foldi on T-DXd and Sacituzumab Govitecan in Metastatic Breast Cancer

June 4th 2024

Julia Foldi, MD, PhD, discusses the utility of of T-DXd and sacituzumab govitecan in the treatment of metastatic HER2-low and triple-negative breast cancer.

Dr Hernandez-Ilizaliturri on the Implications of the FDA Approval of Liso-Cel for R/R Follicular Lymphoma

June 4th 2024

Dr Eads on Nivolumab Plus Neoadjuvant Chemoradiation in Esophageal/GEJ Cancer

June 4th 2024

Jennifer R. Eads, MD, discusses neoadjuvant pCR rates with the addition of nivolumab to neoadjuvant chemoradiation in esophageal/GEJ cancer.

Dr Classe on Lymphadenectomy Omission in Advanced Epithelial Ovarian Cancer

June 4th 2024

Jean-Marc Classe, MD, PhD, discusses lymphadenectomy omission following cytoreductive surgery after chemotherapy in advanced epithelial ovarian cancer.